🦎 ANALYST WATCH | 9 July 2026

R01 RAFFLES MEDICAL GROUP

WHAT THE ANALYST SAYS

RHB Research maintains a buy rating with a target price of 1.30 dollars, implying about 40 percent upside plus a yield of roughly 3 percent, framing the recent share price pullback as an attractive entry point ahead of first half results due 27 July. The thesis centres on China, where the group is targeting EBITDA breakeven at one hospital by year end, and on insurance reforms taking effect this year, which the analyst sees as an overlooked earnings catalyst for Raffles Health Insurance as its losses continue to narrow. The stock is also flagged as trading at a discount to regional healthcare peers.

NOTE

For the full report, check RHB Research's published note or your broker platform.

Not financial advice. Iggy's Forensic Compliance Standards apply.